Mouse models for the cure of β-thalassemia and sickle cell anemia

Minerva Biotecnologica

Volumn 15, Issue 2, 2003, Pages 107-121

  Breda, L ^a   Rivella, S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Disease models, animals; Gene transfer techniques; Genetic vectors; Globins; Hemoglobinopathies; Lentivirus; Mice

Indexed keywords

6 O BENZYLGUANINE; BETA GLOBIN; DIHYDROFOLATE REDUCTASE; HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; IRON CHELATING AGENT; LENTIVIRUS VECTOR; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; BETA CHAIN; BETA THALASSEMIA; BLOOD TRANSFUSION; CELL DESTRUCTION; CELL HYPERPLASIA; CLINICAL FEATURE; DISEASE SEVERITY; ERYTHROID CELL; ERYTHROPOIESIS; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE STRUCTURE; GENE TRANSFER; GENETIC COMPATIBILITY; GENETIC SCREENING; HEMOLYSIS; HLA TYPING; HUMAN; IRON CHELATION; MOUSE; NONHUMAN; PRENATAL DIAGNOSIS; REVIEW; SICKLE CELL ANEMIA; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA; LENTIVIRUS;

EID: 0242636124     PISSN: 11204826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of hemoglobin: genetics, pathophysiology and clinical management. Cambridge, UK: Cambridge University Press; 2001.
2. Trudel M, Costantini F. A 3′ enhancer contributes to the stage-specific expression of the human beta-globin gene. Genes Dev 1987;1:954-61.
3. Trudel M, Magram J, Bruckner L, Costantini F. Upstream G gamma-globin and downstream beta-globin sequences required for stage-specific expression in transgenic mice. Mol Cell Biol 1987;7:4024-9.
4. Antoniou M, deBoer E, Habets G, Grosveld F. The human beta-globin gene contains multiple regulatory regions: identification of one promoter and two downstream enhancers. Embo J 1988;7:377-84.
5. Forrester WC, Epner E, Driscoll MC, Enver T, Brice M, Papayannopoulou T et al. A deletion of the human beta-globin locus activation region causes a major alteration in chromatin structure and replication across the entire beta-globin locus. Genes Dev 1990;4:1637-49.
6. Talbot D, Collis P, Antoniou M, Vidal M, Grosveld F, Greaves DR. A dominant control region from the human beta-globin locus conferring integration site-independent gene expression. Nature 1989;338:352-5.
7. Reik A, Telling A, Zitnik G, Cimbora D, Epner E, Groudine M. The locus control region is necessary for gene expression in the human beta-globin locus but not the maintenance of an open chromatin structure in erythroid cells. Mol Cell Biol 1998;18:5992-6000.
8. Bender MA, Reik A, Close J, Telling A, Epner E, Fiering S et al. Description and targeted deletion of 5′ hypersensitive site 5 and 6 of the mouse beta-globin locus control region. Blood 1998; 92:4394-403.
9. Bender MA, Bulger M, Close J, Groudine M. Beta-globin gene switching and DNase I sensitivity of the endogenous beta-globin locus in mice do not require the locus control region. Mol Cell 2000;5:387-93.
10. Ley TJ, Hug B, Fiering S, Epner E, Bender MA, Groudine M. Reduced beta-globin gene expression in adult mice containing deletions of locus control region 5′ HS-2 or 5′ HS-3. Ann N Y Acad Sci 1998;850:45-53.
11. Bender MA, Roach JN, Halow J, Close J, Alami R, Bouhassira EE et al. Targeted deletion of 5′HS1 and 5′HS4 of the beta-globin locus control region reveals additive activity of the DNasel hypersensitive sites. Blood 2001;98:2022-7.
12. Blom van Assendelft G, Hanscombe O, Grosveld F, Greaves DR. The beta-globin dominant control region activates homologous and heterologous promoters in a tissue-specific manner. Cell 1989;56:969-77.
13. Grosveld F, van Assendelft GB, Greaves DR, Kollias G. Position-independent, high-level expression of the human beta-globin gene in transgenic mice. Cell 1987;51:975-85.
14. Philipsen S, Talbot D, Fraser P, Grosveld F. The beta-globin dominant control region: hypersensitive site 2. Embo J 1990;9:2159-67.
15. Talbot D, Philipsen S, Fraser P, Grosveld F. Detailed analysis of the site 3 region of the human beta-globin dominant control region. Embo J 1990;9:2169-77.
16. Li Q, Harju S, Peterson KR. Locus control regions: coming of age at a decade plus. Trends Genet 1999;15:403-8.
17. Talbot D, Grosveld F. The 5′HS2 of the globin locus control region enhances transcription through the interaction of a multimeric complex binding at two functionally distinct NF-E2 binding sites. Embo J 1991;10:1391-8.
18. Jackson JD, Petrykowska H, Philipsen S, Miller W, Hardison R. Role of DNA sequences outside the cores of DNase hypersensitive sites (HSs) in functions of the beta-globin locus control region. Domain opening and synergism between HS2 and HS3. J Biol Chem 1996;271:11871-8.
19. Bungert J, Dave U, Lim KC, Lieuw KH, Shavit JA, Liu Q et al. Synergistic regulation of human beta-globin gene switching by locus control region elements HS3 and HS4. Genes Dev 1995;9:3083-96.
20. Ney PA, Andrews NC, Jane SM, Safer B, Purucker ME, Weremowicz S et al. Purification of the human NF-E2 complex: cDNA cloning of the hematopoietic cell-specific subunit and evidence for an associated partner. Mol Cell Biol 1993;13:5604-12.
21. Fraser P, Pruzina S, Antoniou M, Grosveld F. Each hypersensitive site of the human beta-globin locus control region confers a different developmental pattern of expression on the globin genes. Genes Dev 1993;7:106-13.
22. Johnson KD, Grass JA, Boyer ME, Kiekhaefer CM, Blobel GA, Weiss MJ et al. Cooperative activities of hematopoietic regulators recruit RNA polymerase II to a tissue-specific chromatin domain. Proc Natl Acad Sci U S A 2002;99:11760-5.
23. Li Q, Stamatoyannopoulos G. Hypersensitive site 5 of the human beta locus control region functions as a chromatin insulator. Blood 1994;84:1399-401.
24. Li Q, Zhang M, Han H, Rohde A, Stamatoyannopoulos G. Evidence that DNase I hypersensitive site 5 of the human beta-globin locus control region functions as a chromosomal insulator in transgenic mice. Nucleic Acids Res 2002;30:2484-91.
25. Pasceri P, Pannell D, Wu X, Ellis J. Full activity from human beta-globin locus control region transgenes requires 5′HS1, distal beta-globin promoter, and 3′ beta-globin sequences. Blood 1998;92:653-63.
26. Sharpe JA, Summerhill RJ, Vyas P, Gourdon G, Higgs DR, Wood WG. Role of upstream DNase I hypersensitive sites in the regulation of human alpha globin gene expression. Blood 1993;82:1666-71.
27. Molete JM, Petrykowska H, Bouhassira EE, Feng YQ, Miller W, Hardison RC. Sequences flanking hypersensitive sites of the beta-globin locus control region are required for synergistic enhancement. Mol Cell Biol 2001;21:2969-80.
28. Grosveld F, de Boer E, Dillon N, Gribnau J, McMorrow T, Milot E et al. The dynamics of globin gene expression and position effects. Novartis Found Symp 1998;214:67-79.
29. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 2002;21:3368-76.
30. Sawado T, Halow J, Bender MA, Groudine M. The beta-globin locus control region (LCR) functions primarily by enhancing the transition from transcription initiation to elongation. Genes Dev 2003;17:1009-18.
31. Hanscombe O, Whyatt D, Fraser P, Yannoutsos N, Greaves D, Dillon N et al. Importance of globin gene order for correct developmental expression. Genes Dev 1991;5:1387-94.
32. Milot E, Strouboulis J, Trimborn T, Wijgerde M, de Boer E, Langeveld A et al. Heterochromatin effects on the frequency and duration of LCR-mediated gene transcription. Cell 1996;87:105-14.
33. Wijgerde M, Grosveld F, Fraser P. Transcription complex stability and chromatin dynamics in vivo. Nature 1995;377:209-13.
34. de Krom M, van de Corput M, von Lindern M, Grosveld F, Strouboulis J. Stochastic patterns in globin gene expression are established prior to transcriptional activation and are clonally inherited. Mol Cell 2002;9:1319-26.
35. Dillon N, Trimborn T, Strouboulis J, Fraser P, Grosveld F. The effect of distance on long-range chromatin interactions. Mol Cell 1997;1:131-9.
36. Peterson KR, Stamatoyannopoulos G. Role of gene order in developmental control of human gamma- and beta-globin gene expression. Mol Cell Biol 1993;13:4836-43.
37. Carter D, Chakalova L, Osborne CS, Dai YF, Fraser P. Long-range chromatin regulatory interactions in vivo. Nat Genet 2002;32:623-6.
38. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science 2002; 295:1306-11.
39. Tolhuis B, Palstra RJ, Splinter E, Grosveld F, de Laat W. Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol Cell 2002;10:1453-65.
40. Hu X, Bulger M, Roach JN, Eszterhas SK, Olivier E, Bouhassira EE et al. Promoters of the murine embryonic beta-like globin genes Ey and betah1 do not compete for interaction with the beta-globin locus control region. Proc Natl Acad Sci U S A 2003;100:1111-5.
41. Tuan D, Kong S, Hu K. Transcription of the hypersensitive site HS2 enhancer in erythroid cells. Proc Natl Acad Sci U S A 1992;89:11219-23.
42. Blackwood EM, Kadonaga JT. Going the distance: a current view of enhancer action. Science 1998;281:61-3.
43. Ashe HL, Monks J, Wijgerde M, Fraser P, Proudfoot NJ. Intergenic transcription and transinduction of the human beta-globin locus. Genes Dev 1997;11:2494-509.
44. Kiekhaefer CM, Grass JA, Johnson KD, Boyer ME, Bresnick EH. Hematopoietic-specific activators establish an overlapping pattern of histone acetylation and methylation within a mammalian chromatin domain. Proc Natl Acad Sci U S A 2002;99:14309-14.
45. Bulger M, Groudine M. Looping versus linking: toward a model for long-distance gene activation. Genes Dev 1999;13:2465-77.
46. Dorsett D. Distant liaisons: long-range enhancer-promoter interactions in Drosophila. Curr Opin Genet Dev 1999;9:505-14.
47. Engel JD, Tanimoto K. Looping, linking, and chromatin activity: new insights into beta-globin locus regulation. Cell 2000;100:499-502.
48. Giardina FJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001;38:360-6.
49. Skow LC, Burkhart BA, Johnson FM, Popp RA, Popp DM, Goldberg SZ et al. A mouse model for beta-thalassemia. Cell 1983;34:1043-52.
50. Curcio MJ, Kantoff P, Schafer MP, Anderson WF, Safer B. Compensatory increase in levels of beta minor globin in murine beta-thalassemia is under translational control. J Biol Chem 1986;261:16126-32.
51. Shehee WR, Oliver P, Smithies O. Lethal thalassemia after insertional disruption of the mouse major adult beta-globin gene. Proc Natl Acad Sci U S A 1993;90:3177-81.
52. Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for beta 0-thalassemia. Proc Natl Acad Sci U S A 1995;92: 11608-12.
53. Ciavatta DJ, Ryan TM, Farmer SC, Townes TM. Mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. Proc Natl Acad Sci U S A 1995;92:9259-63.
54. Rivella S, May C, Chadburn A, Riviere I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003;101:2932-9.
55. Fabry ME, Kennan RP, Paszty C, Costantini F, Rubin EM, Gore JC et al. Magnetic resonance evidence of hypoxia in a homozygous alpha-knockout of a transgenic mouse model for sickle cell disease. J Clin Invest 1996;98:2450-5.
56. Fabry ME, Sengupta A, Suzuka SM, Costantini F, Rubin EM, Hofrichter J et al. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. Blood 1995;86:2419-28.
57. Ryan TM, Townes TM, Reilly MP, Asakura T, Palmiter RD, Brinster RL et al. Human sickle hemoglobin in transgenic mice. Science 1990;247:566-8.
58. Greaves DR, Fraser P, Vidal MA, Hedges MJ, Ropers D, Luzzatto L et al. A transgenic mouse model of sickle cell disorder. Nature 1990;343:183-5.
59. Fabry ME, Costantini F, Pachnis A, Suzuka SM, Bank N, Aynedjian HS et al. High expression of human beta S- and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci U S A 1992;89:12155-9.
60. Fabry ME, Nagel RL, Pachnis A, Suzuka SM, Costantini F. High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci U S A 1992;89:12150-4.
61. Popp RA, Popp DM, Shinpock SG, Yang MY, Mural JG, Aguinaga MP et al. A transgenic mouse model of hemoglobin S Antilles disease. Blood 1997;89:4204-12.
62. Rhoda MD, Domenget C, Vidaud M, Bardakdjian-Michau J, Rouyer-Fessard P, Rosa J et al. Mouse alpha chains inhibit polymerization of hemoglobin induced by human beta S or beta S Antilles chains. Biochim Biophys Acta 1988;952:208-12.
63. D'Surney SJ, Popp RA. Oxygen association-dissociation and stability analysis on mouse hemoglobins with mutant alpha- and beta-globins. Genetics 1992;132:545-51.
64. Trudel M, De Paepe ME, Chretien N, Saadane N, Jacmain J, Sorette M et al. Sickle cell disease of transgenic SAD mice. Blood 1994;84:3189-97.
65. Paszty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997;278:876-8.
66. Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease. Science 1997;278:873-6.
67. Chang JC, Lu R, Lin C, Xu SM, Kan YW, Porcu S et al. Transgenic knockout mice exclusively expressing human hemoglobin S after transfer of a 240-kb betas-globin yeast artificial chromosome: A mouse model of sickle cell anemia. Proc Natl Acad Sci U S A 1998;95:14886-90.
68. Skarpidi E, Vassilopoulos G, Li Q, Stamatoyannopoulos G. Novel in vitro assay for the detection of pharmacologic inducers of fetal hemoglobin. Blood 2000;96:321-6.
69. Vadolas J, Wardan H, Orford M, Voullaire L, Zaibak F, Williamson R et al. Development of sensitive fluorescent assays for embryonic and fetal hemoglobin inducers using the human beta-globin locus in erythropoietic cells. Blood 2002;100:4209-16.
70. Fibach E, Bianchi N, Borgatti M, Prus E, Gambari R. Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood 2003;102:1276-81.
71. Peterson KR, Clegg CH, Li Q, Stamatoyannopoulos G. Production of transgenic mice with yeast artificial chromosomes. Trends Genet 1997;13:61-6.
72. Rivella S, Sadelain M. Therapeutic globin gene delivery using lentiviral vectors. Curr Opin Mol Ther 2002;4:505-14.
73. Ellis J, Pasceri P, Tan-Un KC, Wu X, Harper A, Fraser P et al. Evaluation of beta-globin gene therapy constructs in single copy transgenic mice. Nucleic Acids Res 1997;25:1296-302.
74. May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000;406:82-6.
75. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002;99:1902-8.
76. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001;294:2368-71.
77. Nagel RL, Bookchin RM, Johnson J, Labie D, Wajcman H, Isaac-Sodeye WA et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A 1979;76:670-2.
78. Trudel M, Saadane N, Garel MC, Bardakdjian-Michau J, Blouquit Y, Guerquin-Kern JL et al. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. Embo J 1991;10:3157-65.
79. Paszty C. Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Curr Opin Hematol 1997;4:88-93.
80. May C, Sadelain M. A promising genetic approach to the treatment of beta-thalassemia. Trends Cardiovasc Med 2001;11:276-80.
81. Bethel CA, Muragesh D, Harrison MR, Mohandas N, Rubin ER. Fetal hematopoietic stem cell transplantation into beta-thalassemic mice. J Pediatr Surg 1993;28:1232-7; discussion 1237-8.
82. Kapelushnik J, Or R, Filon D, Nagler A, Cividalli G, Aker M et al. Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. Blood 1995;86:3241-6.
83. Kapelushnik J, Naparstek E, Nagler A, Filon D, Oppenheim A, Amar A et al. Second transplantation using allogeneic peripheral blood stem cells in a beta-thalassaemia major patient featuring stable mixed chimaerism. Br J Haematol 1996;94:285-7.
84. Kwok WW, Schuening F, Stead RB, Miller AD. Retroviral transfer of genes into canine hemopoietic progenitor cells in culture: a model for human gene therapy. Proc Natl Acad Sci U S A 1986;83:4552-5.
85. Williams DA, Hsieh K, DeSilva A, Mulligan RC. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med 1987;166:210-8.
86. Allay JA, Persons DA, Galipeau J, Riberdy JM, Ashmun RA, Blakley RL et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 1998;4:1136-43.
87. Allay JA, Spencer HT, Wilkinson SL, Belt JA, Blakley RL, Sorrentino BP. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 1997;90:3546-54.
88. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992;257:99-103.
89. Flasshove M, Banerjee D, Leonard JP, Mineishi S, Li MX, Bertino JR et al. Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Hum Gene Ther 1998;9:63-71.
90. Allay JA, Koc ON, Davis BM, Gerson SL. Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. Clin Cancer Res 1996;2:1353-9.
91. Davis BM, Reese JS, Koc ON, Lee K, Schupp JE, Gerson SL. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1997;57:5093-9.
92. Reese JS, Koc ON, Lee KM, Liu L, Allay JA, Phillips WP Jr et al. Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc Natl Acad Sci U S A 1996;93:14088-93.
93. Zielske SP, Gerson SL. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol Ther 2002;5:381-7.
94. Persons DA, Allay ER, Sawai N, Hargrove PW, Brent TP, Hanawa H et al. Successful treatment of murine beta-thalassemia using in vivo selection of genetically-modified, drug-resistant hematopoietic stem cells. Blood 2003;102:506-13.
95. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-93.
96. Check E. Cancer risk prompts US to curb gene therapy. Nature 2003;422:7.
97. Rivella S, Callegari JA, May C, Tan CW, Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol 2000;74:4679-87.